drugset
drugset / Trial / NCT06471946

VA Conditioning Regimen Allo-HSCT for Elderly Higher-risk MDS

NCT06471946 ↗

Phase 1/2 Recruiting 54 enrolled Navy General Hospital, Beijing
NaSingle-groupOpen-labelTreatment

Summary

The goal of this phase 1/2 trial is to test the safety and efficacy of Venetoclax Plus Azacytidine Conditioning Regimen Allo-HSCT in treating patients with higher-risk MDS.

Timeline

Start
2024-10-01
Primary completion
2029-09-01
Completion
2030-09-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Azacytidine Other / unclassified 75 mg/m2 Subcutaneous
Subject Venetoclax Small molecule 400 mg Oral

Indications

myelodysplastic syndrome